| Indication | wet age-related macular degeneration |
| Drug | OLN324 |
| Mechanism of Action | VEGF and Ang2 inhibitor |
| Company | Johnson & Johnson |
| Trial Phase | Phase 3 |
| Category | Corporate & Strategic |
| Sub Category | Acquisition Announced |
| Therapeutic Area | Others |
| Deal Value | $3.3 billion |
| Upfront Acquisition Cost | $2.2 billion |
| Potential Milestone Payments | $1.1 billion |
| Blackstone Life Sciences Investment | $750 million |
| Licensed Drug Origin | Innovent Biologics |
| Comparator Drugs | Vabysmo, Eylea, Lucentis |
| NCT Numbers | NCT07816289, NCT07816315 |
| Ollin's Other Drug | OLN102 |
| Ollin's Other Drug Status | Preclinical development |
| Publication Date | November 16, 2026 |
Johnson & Johnson Acquires Ollin Biosciences for Eye Drug OLN324
Johnson & Johnson announced its acquisition of Ollin Biosciences for up to $3.3 billion, including $2.2 billion upfront and $1.1 billion in milestones, to gain OLN324, a late-stage bispecific antibody. OLN324, which targets VEGF and Ang2, is currently in Phase 3 development for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Blackstone Life Sciences is investing $750 million to support the Phase 3 trials. This acquisition aims to bolster J&J's ophthalmology portfolio with a potential competitor to blockbuster therapies like Roche’s Vabysmo and Regeneron’s Eylea, offering the possibility of stronger and more sustained disease control.
- Johnson & Johnson's acquisition of Ollin Biosciences is valued at up to $3.3 billion, comprising a $2.2 billion upfront payment and $1.1 billion in potential milestone payments. This deal is further supported by a $750 million investment from Blackstone Life Sciences, specifically earmarked for the Phase 3 development of OLN324, highlighting a significant financial commitment to the drug's advancement.
- OLN324 is a bispecific antibody that targets both VEGF and Ang2 proteins, key drivers of retinal disease. Originating from Innovent Biologics, the drug is claimed by Ollin to offer potentially greater potency and longer-lasting effects compared to established treatments like Roche’s Vabysmo, which also targets these proteins, aiming for more effective fluid reduction and extended treatment intervals.
- The acquisition positions OLN324 as a significant contender in the competitive ophthalmology market, particularly for wet AMD and DME, where it will vie with blockbuster drugs such as Vabysmo, Eylea, and Lucentis. OLN324 is currently undergoing multiple Phase 3 studies, comparing its efficacy against Lucentis or Eylea, with prior Phase 1b data supporting its potential.
Persistent Challenges in Wet AMD Treatment Landscape
Despite proven efficacy in trials, current intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration imposes sustained clinical, logistical and financial demands. Real-world outcomes often fall short of trial results due to undertreatment, variable biology, and safety monitoring requirements.
High injection burden and undertreatment in practice: Providing anti-VEGF treatment requires the specialized expertise of retina specialists and is labor intensive and costly, while unresolved retinal fluid and high injection burden remain major challenges. In a German real-life cohort, patients received a mean of 4.3 ± 1.9 and 1.3 ± 2.2 injections in years 1 and 2, respectively, with mean changes in visual acuity scores from baseline to years 1 and 2 of 1.1 ± 15.7 and -0.8 ± 17.2 letters; 98.6% of visits were conducted irregularly with an average of 47.7 ± 36.7 days between visits, and more frequent visits and injections were associated with greater improvements in visual acuity.
Significant inter-individual variability in response: Response to anti-VEGF therapy has been found to be dependent on a variety of factors including patient's age, lesion characteristics, lesion duration, baseline visual acuity (VA) and the presence of particular genotype risk alleles, with a proportion of eyes showing a decline in acuity or morphology despite therapy or requiring very frequent re-treatment. Morphological and functional responses do not necessarily correlate and may be dissociated, with a ceiling effect that can negate functional metrics such as >5 letters improvement when baseline VA is good (ETDRS>70 letters). Poor or non-response may be due to suboptimal dosing, increased dosing intervals, treatment initiation when disease is already at an advanced or chronic stage, cellular mechanisms, lesion type, genetic variation and potential tachyphylaxis, as well as non-clinical factors including poor access to clinics or delayed appointments.
Financial burden and access constraints: Intravitreal anti-VEGF therapy imposes a significant financial burden on patients and healthcare systems, and visual acuity outcomes after bevacizumab and ranibizumab were similar despite the substantially lower cost for bevacizumab compared with ranibizumab.
Ocular safety signals requiring vigilance: Ocular inflammation and increased intraocular pressure after intravitreal injection were the most frequently reported serious ocular adverse events, with endophthalmitis reported in fewer than 1% of anti-VEGF-treated participants. In Medicare patients, rates of endophthalmitis per injection (0.09%), uveitis (0.11%), and vitreous hemorrhage per injection (0.23%) were significantly higher in the anti-VEGF treatment group, with a 102% higher risk of severe ocular complications overall and a 4% increased risk per injection. For brolucizumab, an external safety review committee found a rate of 4.6% for definite or probable IOI, 3.3% for retinal vasculitis, and 2.1% for retinal vascular occlusion in the HAWK and HARRIER trials, while real-world cohorts found IOI in ~4-10% of treated eyes, often occurring early (within 3 months) after initiation.
Limited long-term, quality-of-life and biosimilar evidence: Data for visual function, quality of life, and economic outcomes were sparsely measured and reported, and current evidence for anti-VEGF biosimilars is based on a limited number of studies - particularly for comparison with aflibercept - with sparse long-term safety data, and infrequent assessment of quality of life outcomes.
Frequently Asked Questions
References
- [1] Sunaga T, Maeda M et al.. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration. The Cochrane database of systematic reviews. 2024 Jun 3. 38829176
- [2] Yip PP, Woo CF et al.. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. The British journal of ophthalmology. 2009 Jun. 19273471
- [3] Baumal CR. Wet age-related macular degeneration: treatment advances to reduce the injection burden. The American journal of managed care. 2020 May. 32479026
- [4] Keane PA, Liakopoulos S et al.. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Investigative ophthalmology & visual science. 2008 Jul. 18408176
- [5] Rayess N, Rahimy E et al.. Incidence and clinical features of post-injection endophthalmitis according to diagnosis. The British journal of ophthalmology. 2016 Aug. 26584579
- [6] Hufendiek K, Pielen A et al.. [Strategies of Intravitreal Injections with Anti-VEGF: "Pro re Nata versus Treat and Extend"]. Klinische Monatsblatter fur Augenheilkunde. 2018 Aug. 28114697
- [7] Berco E, Kozlov Y et al.. Comparative Real-World Efficacy of Anti-Vascular Endothelial Growth Factor Agents in Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Study. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2026. 41417677
- [8] Day S, Acquah K et al.. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. American journal of ophthalmology. 2011 Aug. 21664593
- [9] Moraru A, Pînzaru G et al.. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. Romanian journal of ophthalmology. 2017 Jul-Sep. 29450400
- [10] Sivaprasad S. Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration. Clinical ophthalmology (Auckland, N.Z.). 2008 Jun. 19668725
- [11] Solomon SD, Lindsley K et al.. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. The Cochrane database of systematic reviews. 2019 Mar 4. 30834517
- [12] Singh RP, Kaiser PK. Role of ranibizumab in management of macular degeneration. Indian journal of ophthalmology. 2007 Nov-Dec. 17951897
- [13] Alali NM, Aljahdali A et al.. Effectiveness, Safety, and Real-World Experience of Brolucizumab: A Systematic Review. Pharmaceuticals (Basel, Switzerland). 2025 Oct 27. 41304869
- [14] Bodaghi B, Khanani AM et al.. Gains in the current understanding of managing neovascular AMD with brolucizumab. Journal of ophthalmic inflammation and infection. 2023 Nov 23. 37995057
- [15] Bikbov MM, Kazakbaeva GM et al.. Safety of intravitreally applied epidermal growth factor receptor antibody panitumumab. Acta ophthalmologica. 2026 Sep 16. 42747171
- [16] Hafner M, Asani B et al.. Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration. BMJ open ophthalmology. 2025 Jun 1. 40451292
- [17] Shaer A, Yokoi T et al.. Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy. Journal of vitreoretinal diseases. 2026 Jul 19. 42518877
- [18] Ziemssen F, Eter N et al.. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2015 Mar. 25668709
- [19] Amoaku WM, Chakravarthy U et al.. Defining response to anti-VEGF therapies in neovascular AMD. Eye (London, England). 2015 Jun. 25882328
- [20] Solomon SD, Lindsley K et al.. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. The Cochrane database of systematic reviews. 2014 Aug 29. 25170575
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com












